SGBCC 2023 – Webcasts
You may find the webcasts of the 18th St.Gallen International Breast Cancer Conference below.
Scientific Sessions
Opening Ceremony: Welcome, Awards and Award Lectures
Chairs: Michael Gnant (Austria), Beat Thürlimann (Switzerland), Walter Weber (Switzerland)
The St.Gallen Breast Cancer Award Lecture 2023:
The Saga of Theragnostic Biomarkers of Breast Cancer
Giuseppe Viale, Italy
The ESO Umberto Veronesi Memorial Award Lecture 2023:
A global approach to breast cancer management
Benjamin Anderson, WHO
Session 1: News since St. Gallen 2021: Challenges and Opportunities
Surgery of patients with early breast cancer: Quo vadis?
Walter Weber, Switzerland
Access to evidence based radiation therapy for patients with early breast cancer
Philip Poortmans, Belgium
What’s new in systemic treatment of patients with early breast cancer
Roisin Connolly, Ireland
Translational research priorities for patients with early breast cancer
Fabrice André, France
Hot topics in survivorship, patient reported outcomes, and Quality of Life
Ann Partridge, USA
Interactive Session 1
Session 2: Genomic and transcriptomic landscape and ctDNA for disease monitoring and risk stratification
ctDNA dynamics for early assessment of recurrence risk
Nicholas Turner, UK
Molecular imaging in breast cancer
Michel van Kruchten, Netherlands
Webcast not available: Multi-omic machine learning prediction of treatment response
Carlos Caldas, UK
How to assess clinical utility and clinical validity of biomarkers in clinical trials?
Meredith Regan, USA
Session 3: Immunomics in early breast cancer: Where do we stand?
Understanding the anti-cancer immune response: Innate and adaptive responses to breast cancer cells
Sherene Loi, Australia
Tumor microenvironment in early breast cancer
Carsten Denkert, Germany
Multiplexed analysis and spatial histology to predict response
Marleen Kok, Netherlands
The future of breast cancer immunotherapy (PD, PDL, vaccines)
Giuseppe Curigliano, Italy
Special lecture I
The future of innovation: Why are we conducting clinical trials in countries that are unlikely to be able to afford innovative drugs?
Sara Tolaney, USA
Session 4: Hereditary Breast Cancer
Local treatment in patients with high risk hereditary breast cancer
Maria Joao Cardoso, Portugal
Management of patients harboring medium penetrance genes
Christian Singer, Austria
Adjuvant systemic therapy for patients with germline BRCA1/2 mutations
Andrew Tutt, UK
Session 5: The future treatment landscape in the adjuvant setting
Post-neoadjuvant options in triple negative disease: PARPi, capecitabine, checkpoint inhibitors Javier Cortes, Spain
Risk assessment in ER positive disease: Who should receive CDK 4-6 inhibitors?
Angela De Michele, USA
What’s next? Antibody drug conjugates for breast cancer therapy
Cristina Saura, Spain
Integrating new oral SERDs in the adjuvant treatment
David Cameron, UK
Debate 1: Early breast cancer: do we need chemotherapy in low genomic/high clinical risk (ER+/HER2-)?
Interactive Session 2: Too big, too small? Too low, too high? Adjuvant choices when stage and biology do not align.
What to do in discordant scenarios? Small tumors with high biological risk? (Case studies)
Session 6: Locoregional treatment of early breast cancer: I
Patient selection, dose and fractionation for external beam radiotherapy in patients with early breast cancer
Charlotte Coles, UK
Benefits and risks of oncoplastic breast-conserving surgery
Marie-Jeanne Vrancken Peeters, Netherlands
Breast surgery after neoadjuvant therapy
Andrea V. Barrio, USA
Breast surgery for local recurrence
Isabel Rubio, Spain
Session 7: Locoregional treatment of early breast cancer: II
Omission of surgical staging of the axilla
Oreste Gentilini, Italy
Axillary surgery in the adjuvant setting
Jana de Boniface, Sweden
Limited axillary surgery concepts to determine nodal pathologic complete response
Jörg Heil, Germany
De-escalation of axillary radiotherapy – the time has come!
Icro Meattini, Italy
Debate 2: Axillary dissection versus axillary radiation for residual nodal disease after neoadjuvant systemic therapy
Interactive Session 3: Controversies and uncertainties in axillary management
Session 8: Optimizing treatment in patients with HER2 positive breast cancer
Assessing HER2 heterogeneity
Frederique Penault-Llorca, France
Current adjuvant and neoadjuvant approaches
Nadia Harbeck, Germany
Emerging new treatments in HER2 positive breast cancer
Martine Piccart, Belgium
ER positive vs ER negative: tackling diversity in HER2 positive breast cancer
Aleix Prat, Spain
Session 9: Optimizing treatment in patients with triple negative breast cancer
Optimal neoadjuvant and adjuvant therapy for patients with early triple negative breast cancer Hope S. Rugo, USA
Optimal systemic therapy for residual disease in TNBC
Sibylle Loibl, Germany
Tackling triple negative histological subtypes in early breast cancer
Jorge Reis Filho, USA
Can we de-escalate immunotherapy and chemotherapy in TNBC?
Hervè Bonnefoi, France
Debate 3: If you achieve pCR after neoadjuvant, do you need adjuvant therapy?
Session 10: Global Prespective on breast cancer treatment
Breast cancer treatment and research from a global perspective
Benjamin Anderson, World Health Organization
Perspective from Asia
Binghe Xu, China
Perspective from Africa
Heba Gamal, Egypt
Perspective from Latin America
Denisse Bretel, Peru
Session 11: Optimizing treatment in patients with HR positive breast cancer
What to do when there are many options? Integrating Olaparib in BRCA-associated ER positive tumors Sara Brucker, Germany
Pre-menopausal: Who needs chemotherapy in the (neo)adjuvant setting?
Prudence Francis, Australia
Can we omit adjuvant endocrine therapy?
Fatima Cardoso, Portugal
Duration of endocrine therapy in early breast cancer
Jens Huober, Switzerland
Debate 4: Surgery of the primary for stage IV disease
SGBCC Academy
Stefan Aebi: Endocrine therapies in early breast cancer
Meteb Al-Foheidi: Immunotherapy for early breast cancer – who benefits?
Carlos Barrios: Adequate treatment for early breast cancer in LMIC ?
Jonas Bergh: Chemotherapy in early breast cancer – who benefits?
Sara Brucker: Early Detection, Diagnosis of Breast Cancer, quality control and Public Health Aspects
Fatima Cardoso: The importance of defining standards of care for breast cancer
Gerd Fastner: Modern radiotherapy for early breast cancer
Chiun-Sheng Huang (ROC): Preop MRI: helpful or dangerous for the breast surgeon?
Miguel Martin: New drugs on the horizon for early breast cancer
Emiel Rutgers: Breast Surgery Standards in 2023
Elzbieta Senkus-Konefka: Overtreament in early breast cancer-who is at risk?
Masakazu Toi: Luminal B-like cancers and neoadjuvant systemic therapy – who benefits?
Toru Watanabe: Gene signatures – who benefits?
Hans Wildiers: Systemic therapy in older persons for early breast cancer
Jiang Zefei: CDK4/6 Inhibition in early breast cancer – who benefits?
